Antiandrogen treatments for persistent adult female acne are oral spironolactone, combined oral contraceptives, and topical clascoterone. Antiandrogens block androgen signals that can raise sebum and inflammation, and trials show modest or uncertain gains with design limits and safety trade-offs. Persistent means facial acne that continues into adulthood and needs systemic therapy after topicals. Designs shape what readers can trust, because dose, comparator, endpoint, and follow-up differ across trials.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What did the main spironolactone trials test?
- How strong is the pooled evidence?
- Where do guidelines place these options?
- What safety and practical checks matter?
What did the main spironolactone trials test?
The SAFA trial enrolled 410 adult women with persistent facial acne needing systemic therapy. It was a pragmatic multicentre phase-3 double-blind trial in England and Wales, testing spironolactone 50 mg daily rising to 100 mg daily versus placebo to week 24, with usual topicals allowed, according to the BMJ in the BMJ trial report. The primary endpoint was acne-specific quality-of-life symptom score at 12 weeks.
Scores were 19.2 on spironolactone versus 17.8 on placebo, a modest significant gain that widened by 24 weeks, with more self-reported improvement and more headaches. The French FASCE trial used a different comparison. It randomized 133 adult women with moderate acne to spironolactone 150 mg daily for 6 months versus doxycycline 100 mg daily for 3 months then placebo, finding greater investigator-rated success on spironolactone at 6 months with odds ratio 2.87, as summarized by Cutis via MDedge in the Cutis practical summary.
How strong is the pooled evidence?
A 2025 systematic review and meta-analysis of randomized placebo-controlled trials of oral spironolactone in women found lesion and severity improvement. The authors flagged small samples, varied outcome measures, and the need for trial sequential analysis before firm efficacy claims. That caution matters for shopping decisions. One trial may measure quality of life, another may measure lesion counts, and another may measure global success.
Results do not convert cleanly into one expected clearing rate. Duration also matters. SAFA followed participants to 24 weeks, FASCE reported at 6 months, and contraceptive trials often need at least three cycles before judging acne response. Slow onset can look like failure when it is normal timing.
Where do guidelines place these options?
The American Academy of Dermatology 2024 acne guidelines give only conditional recommendations for spironolactone, combined oral contraceptives, and topical clascoterone. Conditional means lower certainty or case-by-case use after considering benefits, risks, values, and alternatives. Strong recommendations went to benzoyl peroxide, retinoids, antibiotics, and isotretinoin for severe acne.
For a reader, that split means antiandrogens are options to discuss, not automatic first-line therapy. Combined oral contraceptives reduced inflammatory and noninflammatory lesions versus placebo across 31 trials, with little difference between formulations. Users still need contraceptive counseling because acne benefit does not remove clotting and suitability limits.
What safety and practical checks matter?
Topical clascoterone offers a local approach. Clascoterone 1% cream twice daily is an androgen-receptor inhibitor that reduces sebum and inflammation, FDA-approved Aug.
27, 2020 for acne vulgaris in males and females age 12 and older after two phase-3 trials in moderate-to-severe acne, as described in a PMC review in the PMC clinical review. Oral spironolactone and contraceptives need direct medical screening. AAD 2024 advises no routine potassium testing for healthy young women on spironolactone, but testing for older age, kidney disease, or interacting drugs, plus contraception because spironolactone carries feminization risk and is pregnancy category C.
- Ask about pregnancy plans, blood clot history, migraine with aura, smoking, blood pressure, kidney disease, and potassium-affecting drugs.
- Clarify current topicals, antibiotic history, acne severity, cycle-related flares, and treatment timeline.
- Plan follow-up for blood pressure, side effects, mood, headache, dizziness, breast tenderness, and acne photos or lesion counts.
- Seek prompt care for leg swelling or pain, chest pain, severe headache, vision changes, very low urine output, muscle weakness, or signs of pregnancy.
You Might Also Like
- Limited Topical Spironolactone Evidence in the 2026 Review: Study Design and Evidence Limits for Adults With Persistent Acne
- Topical Clascoterone Evidence Revisited in 2026: What the Findings Mean for Adults With Persistent Acne
- Mediterranean and Vegan Diet Claims in the 2026 Acne Review: Questions Adults With Persistent Acne Can Ask a Dermatologist